@Misspelly if I had to pick my favourite slide, we know that Bisantrene is protective in vitro against cardiotoxicity induced by anthracyclines and Proteasome inhibitors. Therefore a 4 in 7 chance (I.e. 57%) that cardioprotection translates across all the drug classes mentioned. This is on pure probability alone but promising to say the least. Or 5 in 6 (83% if antimetablilolite is excluded as an outlier).
DYOR.
CPACS: Research, Results, Market Comparisons, and Valuations, page-72
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.60 |
Change
-0.010(0.62%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $56.10K | 35.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 110 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 1916 | 4 |
View Market Depth
| Last trade - 11.30am 13/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |